
Eli Lilly has signed an oncology research collaboration and licensing agreement with Stipple Bio, a privately held biotech firm, that could be worth up to $5.9 billion to the smaller company, according to a statement from Stipple Bio. The deal gives the pharmaceutical giant access to technology designed to identify molecules that distinguish cancer cells from healthy tissue, technology Stipple says may help Lilly develop more effective therapies with fewer side effects.
Under the agreement, Stipple Bio will be eligible to receive aggregate payments of up to $5.9 billion tied to research, product development and commercialization milestones, as well as tiered royalties on any resulting product sales, according to Stipple Bio's announcement. In exchange, Lilly receives exclusive worldwide rights to develop and commercialize any products that emerge from the partnership. Stipple will also receive an upfront payment and an equity investment from Lilly, though neither company disclosed the size of those payments, as reported by KFGO. Lilly declined to comment beyond its announcement of the deal.
How the Technology Is Supposed to Work
At the center of the agreement is Stipple's Pointillist Platform, which the company says it will use to discover novel tumor-specific cell-surface epitope binders. Lilly will then combine those binders with its own proprietary oncology technologies, per the GlobeNewswire release. The goal, per KFGO's reporting, is to help Lilly build more precise cancer treatments by targeting molecules that set tumor cells apart from healthy ones.
Stipple Bio is based in Cambridge, Massachusetts, and is simultaneously developing its own pipeline of precision oncology therapies. The company's lead candidate is STP-100, a first-in-class antibody-drug conjugate. Stipple plans to initiate a Phase 1 clinical trial for STP-100 in early 2027 targeting solid tumors, including pancreatic cancer, according to the same announcement.
A $100 Million Series A
Stipple Bio emerged from stealth mode earlier this year with a sizable war chest. BioSpace reported that the company raised its $100 million Series A in June.
Lilly's Broader Oncology Push
The Stipple pact fits into a pattern of aggressive dealmaking for Lilly as the company expands its oncology pipeline while seeking growth beyond its diabetes and obesity medicines, per KFGO. Lilly's existing oncology portfolio includes the breast cancer drug Verzenio and the blood cancer drug Jaypirca, and the company is also developing experimental targeted therapies, antibody-drug conjugates and immuno-oncology medicines, KFGO reported.
BioSpace described Lilly as chasing earlier-stage business-development bets to build out a longer-term pipeline, and the Stipple agreement was one of two deals the company announced the same day, alongside an up-to-$1.5-billion buyout of blood cancer-focused Calytrix Bio — a deal BioSpace said marked Lilly's 14th M&A transaction of the year. The station's report also noted that the pace has been brisk in recent weeks: Fierce Biotech found that over the preceding six weeks, Lilly struck an $870 million expansion of its Gate Bioscience alliance and committed up to $1.1 billion to partner with Metis TechBio, in addition to the Calytrix purchase.









